MSL) serves as field-based medical resource for compliant scientific exchange on Rigel pipeline, areas of research, approved products, and associated disease states with healthcare providers, patient advocacy groups, payors, other industry partners, as well as internal colleagues at Rigel. MSL will be on supporting Rigel's approved oncology products for metastatic breast cancer and lung cancer, but may require support of other approved products in hematology/oncology, as well as supporting any development or launch-related activities for Rigel's pipeline, or in-licensed molecules.